Measles
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- A highly contagious viral infection caused by the measles virus. Symptoms appear 8-12 days after exposure and include a rash, cough, fever and muscle pains that can last 4-7 days. Measles vaccines are available to provide prophylaxis, usually combined with mumps and rubella vaccines (MMR).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Measles
- Therapeutic area
- Infectious Disease
- measles
- Measles morbillivirus caused disease or disorder
- Measles morbillivirus disease or disorder
- Measles morbillivirus infectious disease
- morbilli
- rubeola infection
- rubeola
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0004619
- Parent condition
- MONDO:0005857
Related records
Broader conditions (10)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Mononegavirales infectious disease
- Morbillivirus infectious disease
- Paramyxoviridae infectious disease
- Primary viral infectious disease
- Viral infectious disease
Trials (124)
- 300 Antibody Diagnostic Test Kit
- A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
- A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group
- A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
- A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
- A Study of ProQuad™ in Healthy Children in Korea (V221-023)
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
- A Tool Kit to Improve Vaccine Confidence in the Philippines
- Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
- Barriers and Facilitators to MMR Vaccination Among Healthcare Workers
- Clinical Diagnostic Performance Evaluation of a Measles Rapid Test in Senegal
- Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
- Co-administration Study of OCV, TCV and MR
- Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
Approved drugs (1)
- Measles virus, live attenuated
Drugs in development (5)
- Measles virus vaccine live Phase 2
- Mumps virus vaccine live Phase 2
- Rubella virus vaccine live Phase 2
- Sulfamethoxazole Phase 3
- Trimethoprim Phase 3
Other linked drugs (2)
- Mumps virus, live attenuated
- Rubella virus, live attenuated